A real world study of enzalutamide or abiraterone acetate in metastatic castration-resistant prostate cancer patients

Trial Profile

A real world study of enzalutamide or abiraterone acetate in metastatic castration-resistant prostate cancer patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2018 New trial record
    • 10 Feb 2018 Results of a study comparing healthcare resource utilization and costs for patients treated with Enzalutamide or Abirateron acetate in the U.S presented at the 2018 Genitourinary Cancers Symposium
    • 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top